LYPD2 inhibitors represent a specialized class of chemical compounds designed to target and inhibit the activity of the LYPD2 protein, a member of the Ly6/uPAR family. LYPD2, or Ly6/PLAUR domain-containing protein 2, is a cell surface glycoprotein that is typically involved in cell signaling and various physiological processes. The Ly6/uPAR family is known for its roles in regulating signal transduction, often through interactions with other proteins and lipid membranes. LYPD2, in particular, contains characteristic cysteine-rich domains that are stabilized by disulfide bonds, which give it a distinctive three-fingered structural motif. This structure is critical for its interaction with other molecular entities, particularly in processes related to cell adhesion, migration, and differentiation. The inhibition of LYPD2 is an area of interest for researchers studying cellular processes that involve communication across cell membranes, where precise control over protein interactions can yield significant insights.
Chemically, LYPD2 inhibitors are diverse in their structure but generally share certain properties that allow them to bind effectively to the active sites or regulatory regions of the LYPD2 protein. These inhibitors are often designed to either disrupt the binding interface between LYPD2 and its interaction partners or to modify the protein's conformational state, thereby impeding its normal biological function. The development of these inhibitors involves extensive study of the protein's structure, often leveraging techniques like X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to identify potential binding sites. Additionally, computer-aided molecular docking simulations play a critical role in designing inhibitors that are both specific and potent. The exact nature of the interaction between LYPD2 and its inhibitors is highly dependent on the compound's ability to mimic natural ligands or substrates, making structural complementarity an essential consideration in their development.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, potentially affecting JNK signaling pathways associated with LYPD2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can modulate cellular signals potentially involving LYPD2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor which can affect pathways LYPD2 might be associated with. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-κB pathway inhibitor, potentially dampening any NF-κB signaling where LYPD2 plays a role. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
Targets the IKK complex, potentially affecting any NF-κB pathways associated with LYPD2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that can suppress pathways that LYPD2 might be a part of. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Affects NF-κB signaling, potentially reshaping any downstream activities of LYPD2. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
c-Raf kinase inhibitor, which might affect downstream signaling of pathways associated with LYPD2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor which might modulate cell growth and proliferation pathways linked with LYPD2. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
CDK inhibitor that can potentially affect cell cycle regulation pathways associated with LYPD2. | ||||||